Navigation Links
Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:8/16/2013

yrronium bromide, a long-acting muscarinic antagonist (LAMA), for COPD in pMDI, and
  • PSX2000 MCP™ Series, novel combination medicines designed specifically for respiratory diseases and based on Prosonix proprietary Multi-component Particles™ that uniquely do not require additional functional excipients or co-suspension agents for optimal formulation performance from pMDI or Dry Powder Inhalers (DPI).
  • Prosonix has raised more than £22 million from experienced life sciences investors including Ventech, Gimv, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures, plus £1.3 million from the Biomedical Catalyst.

    For more information, please contact:
    David Hipkiss, CEO
    +44-(0)1865-784-250
    david.hipkiss@prosonix.co.uk

    Mark Swallow, Sita Shah, David Dible
    Citigate Dewe Rogerson
    +44-(0)207-638-9571
    prosonix@citigatedr.co.uk


    '/>"/>
    SOURCE Prosonix
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
    2. Accelerate Diagnostics Announces Final Results of Rights Offering
    3. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
    4. Accelerate Diagnostics Announces Final Terms of Rights Offering
    5. Non-Toxic, Non-Surgical Medical Cancer Therapies Finally Available in the U.S.
    6. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
    7. Finalists Announced for Israel Brain Technologies Million Dollar Global B.R.A.I.N. Prize
    8. Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results
    9. Is There Finally A Way To Stop Severe Excessive Sweating?
    10. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
    11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
    (Date:3/4/2015)... 4, 2015 Following the reintroduction of ... Center (LAC) released a report today urging policymakers ... and heroin epidemic through more effective use of ... "The Case for Expanding Access to Medication-Assisted Treatment ... the health, justice, and economic advantages of medication-assisted ...
    (Date:3/4/2015)... 2015  Heska Corporation (Nasdaq: HSKA ) ... Join Its Fourth Quarter and Year End 2014 Earnings ... 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: www.heska.com ... Call link on the front page of this website)How:Live ... web at the address above.  Alternatively, you may use ...
    Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
    ... , MELVILLE, N.Y. , Jan. 25 ... provider of health care products and services to office-based practitioners, announced today ... and Chief Financial Officer, will present at the Jefferies 2010 Global Healthcare ... Schein,s presentation is scheduled to begin at 3:30 p.m. EST ...
    ... , , RYE, N.Y. , ... a drug research and development company focused on the treatment of neurological ... clinical trials for CM-AT, its autism treatment, at ten sites across the ... New York City Drexel University , Philadelphia ...
    Cached Medicine Technology:Henry Schein To Present At The Jefferies 2010 Global Healthcare Services Conference 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4
    (Date:3/4/2015)... (PRWEB) March 04, 2015 The federal ... allege the statin drug caused patients to develop Type ... District Court, District of South Carolina. According to court ... on March 26, 2015 at 10:00 a.m. In advance ... submit a Joint Status report to the Court by ...
    (Date:3/4/2015)... The ability of volumetric breast imaging ... help improve breast cancer risk prediction models is ... at the European Congress of Radiology (ECR) meeting, ... posters and 2 session presentations - highlight the ... quantitative breast imaging software tools to provide insight ...
    (Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
    (Date:3/4/2015)... March 04, 2015 The print component ... The San Francisco Chronicle with a circulation of approximately ... Its digital component is distributed nationally through a vast ... news sites and partner outlets. To explore the digital ... , Milorganite is composed of heat-dried microbes that have ...
    (Date:3/4/2015)... The Global Liquefied Petroleum Gas Market was ... estimated to grow to $288.7 billion by 2019, ... 2019. , Browse through the TOC of Global ... industry trends, segments & forecasts., http://www.micromarketmonitor.com/market-report/liquid-petroleum-gas-reports-5046983367.html ... is classified into source, application, and region. The ...
    Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
    ... Starting the morning of Feb. 1, two,giant heart-shaped ... of,Michigan,s downtown Detroit headquarters building and remind women to ... February, the 11-story high heart displays will adorn both,the ... on East,Lafayette near I-375 in downtown Detroit. The large ...
    ... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
    ... of Alabama at Birmingham have uncovered important new information about ... replicate and wreak havoc on the immune system. , The ... viruses work to subvert the immune system, the researchers say. ... used to develop new drugs to combat a variety of ...
    ... most hospitals already stocked with simple, inexpensive solution , , THURSDAY, ... (magnesium sulfate) given just before delivery to pregnant women at ... palsy among these newborns in half, U.S. researchers report. , ... United States. All the women were at high risk for ...
    ... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
    ... Jan. 31 MQ Associates, Inc. ("MQ,Associates") announced ... tender offer and consent solicitation with respect to ... (CUSIP No. 55345RAC2) (the "Notes").,The tender offer and ... on January 29, 2008 (the "Expiration Date")., ...
    Cached Medicine News:Health News:Heart-Shaped Light Displays on Blue Cross Blue Shield of Michigan Building Show Support for American Heart Month, National Wear Red Day 2Health News:Oregon researchers find trigger gene for muscle development 2Health News:Researchers uncover more about how poxviruses evade the immune system 2Health News:Researchers uncover more about how poxviruses evade the immune system 3Health News:Epsom Salt Cut Cerebral Palsy Rate in Half Among Preemies 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 3
    Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
    Round knurled handle. Overall length 130 mm....
    4.625 inches, curved blade 4 mm....
    Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
    Medicine Products: